This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Long-Term Safety of Risperidone

Michael Davidson

Published: January 7, 2001

Article Abstract

In 2 pivotal trials comparing risperidone with placebo, the risk of adverse events was similarin both treatment groups when risperidone was given at the optimal clinical dose (1 mg/day). During12-month, open-label extensions to these studies, the incidence of de novo tardive dyskinesia wasvery low. No clinically significant adverse events, changes in vital signs, or laboratory signs were observed.In summary, the safety and tolerability of risperidone in treating elderly dementia sufferers hasbeen favorable in several clinical trials.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: Neurologic and Neurocognitive , Neurology

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...

Read More...